Biodesix, Inc. (BDSX)
23.66
-0.21
(-0.88%)
USD |
NASDAQ |
Oct 21, 11:44
Biodesix Research and Development Expense (TTM) : 12.28M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.28M |
| March 31, 2026 | 12.42M |
| December 31, 2025 | 12.00M |
| September 30, 2025 | 11.54M |
| June 30, 2025 | 11.10M |
| March 31, 2025 | 10.39M |
| December 31, 2024 | 9.559M |
| September 30, 2024 | 9.034M |
| June 30, 2024 | 8.425M |
| March 31, 2024 | 8.777M |
| December 31, 2023 | 9.988M |
| September 30, 2023 | 11.66M |
| June 30, 2023 | 12.70M |
| Date | Value |
|---|---|
| March 31, 2023 | 13.15M |
| December 31, 2022 | 13.10M |
| September 30, 2022 | 12.39M |
| June 30, 2022 | 12.71M |
| March 31, 2022 | 12.67M |
| December 31, 2021 | 12.79M |
| September 30, 2021 | 13.04M |
| June 30, 2021 | 12.46M |
| March 31, 2021 | 11.24M |
| December 31, 2020 | 10.82M |
| September 30, 2020 | 10.22M |
| June 30, 2020 | 9.868M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Quest Diagnostics, Inc. | -- |
| Labcorp Holdings, Inc. | -- |
| OPKO Health, Inc. | 125.22M |
| Psychemedics Corp. | -- |
| NeoGenomics, Inc. | 38.17M |